Abstract: Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 momoered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.

Abstract: A pharmaceutical composition for parenteral administration is disclosed which comprises from about 0.01% to about 30% of a .beta.-adrenergic blocking compound of the formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic group or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.2 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.

Abstract: Described is a process for preparing 2,2'-disubstituted-1,3-dioxolane-4-methanol compounds having the formula ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen, alkyl, cycloalkyl or R.sub.1 and R.sub.2 together with the carbon atom form a 3 to 6 member cycloalkyl group, or aryl, the process comprising: reacting D- or L-serine with a nitrosating agent in an aqueous solution in the presence of formic acid, acetic acid, or propanoic acid to prepare 2,3-dihydroxypropanoic acid (D- or L-glyceric acid), the aqueous solution comprising from about 0.1 to 0.5 liter of water per mole of the serine starting material; reacting the glyceric acid so formed with 2,2-dimethoxypropane in the presence of a loweralkyl alcohol to prepare the D- or L-glyceric acid alkyl ester which is reacted with a selected aldehyde or ketone or the acetal or ketal derivative to prepare the corresponding 1,3-dioxolane derivative.

Abstract: The present invention relates to new compounds of the formula ##STR1## where X is ##STR2## alkylene, or --S-- where R.sub.1 is hydrogen, alkyl, or aryl; W is hydrogen, hydroxy, amino, alkyloxy, aryloxy, O-alkyl, or O-aralkyl; (Y).sub.A is --CH.sub.2 NR.sub.2 R.sub.3 where R.sub.2 and R.sub.3 may be hydrogen, substituted alkyls, aryls, or together with N form a 5 to 7 membered heterocyclic group; and Ar is a substituted or unsubstituted aryl. These compounds are useful in the treatment of various cardiac arrhythmias.

Abstract: A method for the treatment of glaucoma or lowering intraocular pressure in a mammal, involving topically administering to the eye of such mammal a selectively metabolized beta-blocking compound of the formula: ##STR1## wherein Ar may be substituted or unsubstituted aromatic, Y may be a straight or branched carbon chain or aralkyl, R may be lower alkyl, lower alkenyl, lower alkynyl, aryl, or aralkyl, and x is an integer from 1 to about 3; or a pharmaceutically acceptable salt thereof. Because of a relatively long duration of action of such compounds in ocular fluids and a relatively short duration of action in the systemic circulation, such compounds are useful for the treatment of excessive intraocular pressure without substantial systemic effects.

Abstract: Described herein are compounds of the formula ##STR1## wherein R.sub.1 is alkyl of from 1 to about 5 carbon atoms, alkenyl of from 2 to about 5 carbon atoms, alkynyl of from 3 to about 5 carbon atoms, cycloalkyl of from 3 to about 7 carbon atoms, alkylcarboxymethyl wherein the alkyl portion is from 1 to about 5 carbon atoms, arylcarboxymethyl wherein the aryl portion is from 6 to about 10 carbon atoms, aryl of from 6 to about 10 carbon atoms, or aralkyl wherein the alkyl portion is from 1 to about 5 carbon atoms and the aryl portion is from about 6 to about 10 carbon atoms; R.sub.2 and R.sub.

Abstract: Described are compounds of the formula ##STR1## wherein R is hydrogen, lower alkyl, halo, cyano, hydroxy, amino, lower alkylamino, --CH.sub.2 NH.sub.2, CH.sub.2 OH or COOR"; R' is hydrogen, lower cycloalkyl or lower alkyl; R" is lower alkyl or --CH.sub.2 Ar wherein Ar is phenyl, substituted phenyl, furan or thiophene; R'" is COOR", ##STR2## and x is oxygen or nitrogen; or a pharmaceutically acceptable salt thereof and their use in the treatment of impaired ventricular myocardial contractility.The compounds exhibit cardiotonic activity.

Abstract: Disclosed is a process for preparing optically active alpha-aminonitriles of the formula ##STR1## by the reaction of alpha-trimethylsilyloxynitriles with optically active alpha-methylbenzylamine in the presence of a loweralkyl alcohol.In the above formula, R denotes C.sub.1 -C.sub.20 alkyl, C.sub.3 -C.sub.12 cycloalkyl, C.sub.7 -C.sub.15 aralkyl or unsubstituted or substituted aryl or heteroaryl.In general, R-alpha-methylbenzylamine gave I and III as the major and the minor products, respectively. Whereas, S-alpha-methylbenzylamine gave II and IV as the major and the minor products, respectively.The compounds so prepared are intermediates in the preparation of optically active aminoacids.

Abstract: Described is a process for preparing alpha-aminonitriles having the formula ##STR1## where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen, C.sub.1 -C.sub.20 alkyl, C.sub.3 -C.sub.12 cycloalkyl, C.sub.7 -C.sub.15 aralkyl, unsubstituted or substituted aryl or heteroaryl or alternatively, R.sub.1 and R.sub.2 together with the carbon atom form a 3 to 12 member cycloalkyl group, or with a heteroatom form a 3 to 12 member heterocyclic group and R.sub.3 and R.sub.4 together with the nitrogen atom form a 3 to 12 member heterocyclic group and R.sub.3 and R.sub.

Abstract: Described are compounds of the formula ##STR1## wherein R is heteroaryl and R.sub.1 is hydrogen or loweralkyl, or a pharmaceutically acceptable salt thereof.The compounds exhibit cardiotonic activity.

Abstract: Novel compounds are disclosed having the formula ##STR1## wherein R is lower alkyl, lower cycloalkyl, lower haloalkyl, lower alkylcarboxymethyl, arylcarboxymethyl, lower alkenyl, lower alkynyl, aryl having from 6 to about 10 carbon atoms, or aralkyl; R.sub.1 is lower alkyl, lower hydroxyalkyl, lower alkenyl, lower alkynyl, aralkyl, or --WB; where W is alkylene containing from 1 to about 10 carbon atoms; and B is --NR.sub.2 COR.sub.3, --NR.sub.2 CONR.sub.3 R.sub.4, --NR.sub.2 SO.sub.2 R.sub.3, --NR.sub.2 SO.sub.2 NR.sub.3 R.sub.4, or --NR.sub.2 COOR.sub.5, where R.sub.2, R.sub.3, R.sub.4, and R.sub.5 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, alkoxyaryl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.3 and R.sub.5 are not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.3 or --NR.sub.2 COOR.sub.5, or R.sub.3 and R.sub.

Abstract: Described are compounds of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 independently of one another denote hydrogen or loweralkyl, X is hydroxy or amino, and Y is hydrogen, loweralkyl, loweralkoxy, benzyl or ##STR2## wherein W and Z independently of one another denote hydrogen, halo, loweralkyl, loweralkoxy, trifluoromethyl, acetamido, cyano, diloweralkylamino, phenoxy and loweralkylmercapto, and pharmaceutically acceptable salts thereof.The compounds are effective as anti-inflammatory agents.

Abstract: Described are compounds of the formula ##STR1## wherein R is hydrogen or loweralkyl, X, Y and W independently of one another denote hydrogen, halogen, loweralkyl, nitro, amino, amido, loweralkoxy, hydroxy, nitrile, methylsulfone, methylsulfoxide, methylmercapto, or trifluoromethyl; Z is oxygen, sulfur or --CH.sub.2 ; n and m are each an integer from 0 to 6 inclusive, or pharmaceutically acceptable salts thereof.The compounds are effective as anti-inflammatory agents.

Abstract: The present invention relates to new compounds of the formula ##STR1## alkylene, or --S-- where R.sub.1 is hydrogen, alkyl, or aryl; W is hydrogen, hydroxy, amino, alkyloxy, aryloxy, O-alkyl, or O-aralkyl; (Y).sub.A is --CH.sub.2 NR.sub.2 R.sub.3 where R.sub.2 and R.sub.3 may be hydrogen, substituted alkyls, aryls, or together with N form a 5 to 7 membered heterocyclic group; and Ar is a substituted or unsubstituted heteroaryl. These compounds are useful in the treatment of various cardiac arrhythmias.

Abstract: Described are compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 independently of one another denote hydrogen or loweralkyl; A is CO, CH.sub.2, O, S, SO or CHOH; X is hydrogen, halo, loweralkyl, or --CH.sub.2 NR.sub.1 R.sub.2 wherein R.sub.1 and R.sub.2 are as defined above; W is COOR wherein R is hydrogen or alkyl of 1-10 carbon atoms, CH.sub.2 OH, CONR.sub.1 R.sub.2 or CH.sub.2 NR.sub.1 R.sub.2 wherein R.sub.1 and R.sub.2 are as defined above; Z.sub.1 and Z.sub.2 independently of one another denote hydrogen, halo or loweralkyl; and pharmaceutically acceptable salts thereof.The compounds are effective as diuretic agents.

Abstract: Described is a method for the preparation of 6'-modified fortimicin compounds including 6'-epi fortimicin by converting 1,2-di-N-protected fortimicin B into 4,6'-di-N-substituted alkoxycarbonyl-1,2'-di-N-protected fortimicin B which is further converted to 1,2'-di-substituted fortimicin B-4,5-carbamate, a compound whose substitution pattern is particularly suited to modification at the 6'-amino group and novel compounds thereof.

Abstract: Described are compounds of the formula ##STR1## wherein R.sub.2 -R.sub.8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR2## with the proviso that at least one but no more than one of the substituents R.sub.2 -R.sub.8 is ##STR3## and with the further provisos that at least four of the substituents R.sub.2 -R.sub.8 are hydrogen and R.sub.2 cannot be ##STR4## when R.sub.3 -R.sub.8 are hydrogen, and pharmaceutically acceptable salts thereof.The compounds are effective as antiinflammatory and antiasthma agents.

Abstract: Described are compounds of the formula ##STR1## wherein R is hydrogen, loweralkyl, aminomethyl or halo; R.sub.1 is carboxy, carboxyloweralkyl, aminocarbonyl, hydroxymethyl, anilinomethyl, or aminomethyl; A is oxygen, CH.sub.2, Sulfur or a single bond; X is oxygen, CH.sub.2, sulfur or sulfoxide; and Y is hydrogen, loweralkyl or halo and may be the same or different, and pharmaceutically acceptable salts thereof.The compounds are effective as diuretic agents.

Abstract: Described are compounds of the formula ##STR1## wherein Y and Z independently of one another denote hydrogen, halo or trihalomethyl, with the proviso that Y and Z cannot both be hydrogen, R is hydrogen or loweralkyl, n is 5 to 19, and pharmaceutically acceptable salts thereof.The compounds are active hypocholesterolemic agents.